Catalytic site mutations confer multiple states of G protein activation.
Natalie HewittNing MaNadia ArangSarah A MartinAjit PrakashJeffrey F DiBertoKevin M KnightSoumadwip GhoshReid H J OlsenBryan L RothJorge Silvio GutkindNagarajan VaidehiSharon L CampbellHenrik G DohlmanPublished in: Science signaling (2023)
Heterotrimeric guanine nucleotide-binding proteins (G proteins) that function as molecular switches for cellular growth and metabolism are activated by GTP and inactivated by GTP hydrolysis. In uveal melanoma, a conserved glutamine residue critical for GTP hydrolysis in the G protein α subunit is often mutated in Gα q or Gα 11 to either leucine or proline. In contrast, other glutamine mutations or mutations in other Gα subtypes are rare. To uncover the mechanism of the genetic selection and the functional role of this glutamine residue, we analyzed all possible substitutions of this residue in multiple Gα isoforms. Through cell-based measurements of activity, we showed that some mutants were further activated and inactivated by G protein-coupled receptors. Through biochemical, molecular dynamics, and nuclear magnetic resonance-based structural studies, we showed that the Gα mutants were functionally distinct and conformationally diverse, despite their shared inability to hydrolyze GTP. Thus, the catalytic glutamine residue contributes to functions beyond GTP hydrolysis, and these functions include subtype-specific, allosteric modulation of receptor-mediated subunit dissociation. We conclude that G proteins do not function as simple on-off switches. Rather, signaling emerges from an ensemble of active states, a subset of which are favored in disease and may be uniquely responsive to receptor-directed ligands.
Keyphrases
- molecular dynamics
- magnetic resonance
- anaerobic digestion
- density functional theory
- single cell
- small molecule
- amino acid
- wild type
- magnetic resonance imaging
- cell therapy
- protein kinase
- mesenchymal stem cells
- cancer therapy
- computed tomography
- bone marrow
- binding protein
- case control
- drug delivery
- neural network
- skin cancer
- dna methylation
- structural basis